Bill Wiesler is the Director of the Blavatnik Fund for Innovation at Yale, a $10 million grant from the Blavatnik Family Foundation that supports efforts to turn Yale faculty discoveries into life science treatments, drugs and devices.
He is also serving as the Director of New Ventures at OCR, a position he has held since 2002. In that role, he works with Yale faculty and students to form new ventures based on Yale technologies of all types, including biotech, pharmaceuticals, medical devices, diagnostics, cleantech, and software. Since 2003, Yale has spun out 57 new companies that have raised over $830 million in venture investment. Bill has played a key role in recruiting entrepreneurs and capital for over half of these ventures and has held numerous Board and Observer seats. He currently serves as a Board Observer of: IsoPlexis, a company developing a single cell immunoassay device; NanoEngineering Corporation, a biosensor company; and TransImmune AG, a company developing ECP-based dendritic cell therapy.
Prior to joining OCR, Bill was with McKinsey & Company, where he served senior management at four of the top ten global pharmaceutical companies on a range of strategic and business development issues. Prior to McKinsey, Bill was with Radius Ventures, a startup and early-stage venture capital firm focused on the health and life sciences industry. Earlier, Bill held research positions at Cadus Pharmaceutical Corp., where he headed drug discovery, and at University of Colorado, where he was an American Cancer Society fellow.
He is a summa cum laude graduate of Princeton University, and earned both an M.B.A. and a Ph.D. in Chemistry from Columbia University.